XDH and COVID-19: In view of the above, the inhibition of XO activity, including in cases caused by a respiratory virus such as SARS-CoV-2, can be used as the target of therapy, especially to maintain the clinical conditions of COVID-19 patients so that the comorbid diseases do not develop into a serious complication that can lead to MOF and resulting in death.